SLN Stock SLN is expected to report earnings to fall -11.14% to -8 cents per share on March 13

A.I.dvisor
at Tickeron.com
05/13/24
Loading...
SLN - Silence Therapeutics Plc
Silence Therapeutics Plc Earnings Graph
Q4'23
Est.
$-0.08
Q3'23
Beat
by $0.10
Q2'23
Beat
by $0.05
Q1'23
Beat
by $0.03
Q4'22
Beat
by $0.46
The last earnings report on September 30 showed earnings per share of -7 cents, beating the estimate of -17 cents. P/B Ratio (46.512) is normal, around the industry mean (10.609). P/E Ratio (0.000) is within average values for comparable stocks, (160.883). SLN's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.422). Dividend Yield (0.000) settles around the average of (0.066) among similar stocks. P/S Ratio (24.814) is also within normal values, averaging (236.959). With 54.57K shares outstanding, the current market capitalization sits at 979.86M.
View a ticker or compare two or three
SLNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
72 Hammersmith Road
Phone
+44 2034576900
Employees
109
Web
https://www.silence-therapeutics.com